Top 5 Drug Type | Count |
---|---|
Small molecule drug | 2 |
Top 5 Target | Count |
---|---|
Muscle-type nAChRs(Muscle-type nicotinic acetylcholine receptor) | 2 |
Target |
Mechanism Muscle-type nAChRs antagonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism Muscle-type nAChRs antagonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism Muscle-type nAChRs antagonists |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date24 May 2021 |
Sponsor / Collaborator |
Start Date19 Oct 2020 |
Sponsor / Collaborator |
Start Date23 Dec 2019 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
MB-444 ( Muscle-type nAChRs ) | Organophosphate Poisoning More | Preclinical |
MB408 ( Muscle-type nAChRs ) | Organophosphate Poisoning More | Preclinical |
MB327 ( Muscle-type nAChRs ) | Organophosphate Poisoning More | Pending |